Skip to main content

Advertisement

SpringerLink
Log in

Pituitary tumor diagnosis and treatment

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Over the past few years, significant contributions have been made to the understanding, diagnosis, and treatment of pituitary tumors. This article reviews recent advances in the areas of biology, diagnostic imaging, medical diagnosis and treatment, surgical results and technique, and adjuvant therapy in the form of radiotherapy and radiosurgery. Of particular note are the roles of endoscopy, intraoperative magnetic resonance imaging, radiosurgery, and radiation for nonfunction tumors, the diagnosis of Cushing’s disease, the management of "incidentalomas," and new medication therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kovacs K, Horvath E, Asa SL: Classification and pathology of pituitary tumors. In Neurosurgery. Edited by Wilkins RH, Rengachary SS. New York: McGraw-Hill; 1985:834–842.

    Google Scholar 

  2. Trautmann K, Thakker RV, Ellison DW, et al.: Chromosomal aberrations in sporadic pituitary tumors. Int J Cancer 2001, 91:809–814.

    Article  PubMed  CAS  Google Scholar 

  3. Bello MJ, de Campos JM, Kusak ME, et al.: Chromosomal abnormalities in pituitary adenomas. Cancer Genet Cytogenet 2001, 124:76–79.

    Article  PubMed  CAS  Google Scholar 

  4. Yu R, Melmed S: Oncogene activation in pituitary tumors. Brain Pathol 2001, 11:328–341.

    Article  PubMed  CAS  Google Scholar 

  5. Suliman M, Royds J, Cullen D, et al.: Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol 2001, 54:317–325.

    Article  CAS  Google Scholar 

  6. Simpson DJ, Frost SJ, Bicknell JE, et al.: Aberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 2001, 22:1149–1154.

    Article  PubMed  CAS  Google Scholar 

  7. Ezzat S: The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathol 2001, 11:356–370.

    Article  PubMed  CAS  Google Scholar 

  8. Alexander JM: Tumor suppressor loss in pituitary tumors. Brain Pathol 2001, 11:342–355.

    Article  PubMed  CAS  Google Scholar 

  9. Schreiber S, Saeger W, Ludecke DK: Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1999, 1:213–220.

    Article  PubMed  CAS  Google Scholar 

  10. Losa M, Franzin A, Mangili F, et al.: Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 2000, 47:1313–1318.

    Article  PubMed  CAS  Google Scholar 

  11. Mastronardi L, Guiducci A, Buttaro FM, et al.: Relationships among DNA Index, S-Phase, and invasive behavior in anterior pituitary adenomas. A cytometric study of 61 cases with Feulgen-positive DNA analysis. Surg Neurol 2001, 56:27–32.

    Article  PubMed  CAS  Google Scholar 

  12. Nakabayashi H, Sunada I, Hara M: Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 2001, 49:1193–1194.

    PubMed  CAS  Google Scholar 

  13. Castro MG, Cowen R, Smith-Arica J, et al.: Gene therapy strategies for intracranial tumors: glioma and pituitary adenomas. Histol Histopathol 2000, 15:1233–1252.

    PubMed  CAS  Google Scholar 

  14. Davis JR, McNeilly AS: Is pituitary gene therapy realistic? Clin Endocrinol 2001, 55:427–433.

    Article  CAS  Google Scholar 

  15. Bolognani F, Goya RG: Gene therapy in the neuroendocrine system: its implementation in experimental models using viral vectors. Neuroendocrinology 2001, 73:75–83.

    Article  PubMed  CAS  Google Scholar 

  16. Castro MG, Southgate T, Lowenstein PR: Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumors. Trends Endocrinol Metab 2001, 12:58–64.

    Article  PubMed  CAS  Google Scholar 

  17. Bonneville JF: Pituitary adenomas: value of MR imaging. J Radiol 2000, 81:939–942.

    PubMed  CAS  Google Scholar 

  18. Gao R, Isoda H, Tanaka T, et al.: Dynamic gadoliniumenhanced MR imaging of pituitary adenomas: usefulness of sequential sagittal and coronal plane images. Eur J Radiol 2001, 39:139–146.

    Article  PubMed  CAS  Google Scholar 

  19. Kiortsis DN, Argyropoulou MI, Efremidis SC, Tsatsoulis A: Hyperprolactinemia induced by a nonsecreting pituitary adenoma: differential diagnosis with magnetization transfer MRI technique. Clin Endocrinol 2001, 55:423–426.

    Article  CAS  Google Scholar 

  20. Kaibara T, Tyson RL, Sutherland GR: Human cerebral neoplasms studied using MR spectroscopy: a review. Biochem Cell Biol 1998, 76:477–486.

    Article  PubMed  CAS  Google Scholar 

  21. Nakano T, Asano K, Tanaka M, et al.: Use of 201T1 SPECT for evaluation of biologic behavior in pituitary adenomas. J Nucl Med 2001, 42:575–578.

    PubMed  CAS  Google Scholar 

  22. Jho HD, Park IS, Alfieri A: The future of pituitary surgery. Clin Neurosurg 2000, 47:83–98. Article clearly and concisely reviews the advantages, disadvantages, and technical aspects of the technique.

    PubMed  CAS  Google Scholar 

  23. Jho HD, Alfieri A: Endoscopic endonasal pituitary surgery: evolution of surgical technique and equipment in 150 operations. Min Invas Neurosurg 2001, 44:1–12.

    Article  CAS  Google Scholar 

  24. Jho HD, Alfieri A: Endoscopic transsphenoidal pituitary surgery: various surgical techniques and recommended steps for procedural transition. Br J Neurosurg 2000, 14:432–440.

    Article  PubMed  CAS  Google Scholar 

  25. Ogawa T, Matsumoto K, Nakashima T, et al.: Hypophysis surgery with or without endoscopy. Auris Nasus Larynx 2001, 28:143–149.

    Article  PubMed  CAS  Google Scholar 

  26. Fahlbusch R, Ganslandt O, Buchfelder M, Schott W, Nimsky C: Intraoperative magnetic resonance imaging during transsphenoidal surgery. J Neurosurg 2001, 95:381–390.

    PubMed  CAS  Google Scholar 

  27. Jane JA, Thapar K, Alden T, Laws ER: Fluoroscopic frameless stereotaxy for transsphenoidal surgery. Neurosurgery 2001, 48:1302–1308.

    Article  PubMed  Google Scholar 

  28. Pillay PK, Leo CW, Sethi DS: Computer-aided/image-guided and video-endoscopic resection of pituitary tumors. Stereotact Funct Neurosurg 2000, 74:203–209.

    Article  PubMed  CAS  Google Scholar 

  29. Biermasz NR, Van Dulken H, Roelfsema F: Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000, 85:4596–4602. A long-term retrospective analysis of 59 acromegalic patients who underwent transsphenoidal tumor resection. It emphasizes the most stringent endocrinologic requirements for determining recurrence, and suggests a higher than previously thought rate of longterm recurrence.

    Article  PubMed  CAS  Google Scholar 

  30. Kreutzer J, Vance ML, Lopes MB, Laws ER: Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001, 86:4072–4077.

    Article  PubMed  CAS  Google Scholar 

  31. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M: Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995, 80:3395–3402.

    Article  PubMed  CAS  Google Scholar 

  32. Bochicchio D, Losa M, Buchfelder M: Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s disease survey study group. J Clin Endocrinol Metab 1995, 80:3114–3120.

    Article  PubMed  CAS  Google Scholar 

  33. Laws EL, Jane JA: Pituitary tumors: long term outcomes and expectations. Clin Neurosurg 2001, 48:306–319. This article provides a thorough summary of classification, medical and surgical management, and long-term outcomes for each of the categories of pituitary tumors.

    PubMed  CAS  Google Scholar 

  34. Gokalp HZ, Deda H, Attar A, et al.: The neurosurgical management of prolactinomas. J Neurosurg Sci 2000, 44:128–132.

    PubMed  CAS  Google Scholar 

  35. Boelaert K, Gittoes N: Radiotherapy for non-functioning pituitary adenomas. Eur J Endocrinol 2001, 144:569–575.

    Article  PubMed  CAS  Google Scholar 

  36. Gittoes NJ, Bates AS, Tse W, et al.: Radiotherapy for non-function pituitary tumours. Clin Endocrinol 1998, 48:331–337.

    Article  CAS  Google Scholar 

  37. Turner H, Stratton I, Byrne J, et al.: Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation—a follow-up study. Clin Endocrinol 1999, 51:281–284.

    Article  CAS  Google Scholar 

  38. Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, Ridgway EC: Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 1998, 43:432–428.

    Article  PubMed  CAS  Google Scholar 

  39. Woollons AC, Hunn MK, Rajapakse YR, et al.: Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol 2000, 53:713–717.

    Article  CAS  Google Scholar 

  40. Ebersold MJ, Quast LM, Laws ERJr, Scheithauer B, Randall RV: Long-term results in transsphenoidal removal of non-functioning pituitary adenomas. J Neurosurg 1986, 64:713–719.

    PubMed  CAS  Google Scholar 

  41. Kim SH, Huh R, Chang JW, Park YG, Chung SS: Gamma knife radiotherapy for functioning pituitary adenomas. Stereotact Funct Neurosurg 1999, 72(suppl 1):101–110.

    Article  PubMed  Google Scholar 

  42. Landolt AM, Lomax N: Gamma knife radiosurgery for prolactinomas. J Neurosurg 2000, 93(Suppl 3):14–18.

    PubMed  Google Scholar 

  43. Iazawa M, Mayashi M, Nakaya K, et al.: Gamma Knife radiosurgery for pituitary adenomas. J Neurosurg 2000, 93(suppl 3):19–22. The proceedings from the 10th International Leksell Gamma Knife Society Meeting, which took place in Lake Tahoe, California, are published in this supplement (pages 1 to 22) and include the most recent, retrospective analyses of the use of Gamma Knife radiosurgery in the treatment of patients with both functional and nonfunctional pituitary adenomas.

    Google Scholar 

  44. Ikeda H, Jokura H, Yoshimoto T: Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormonesecreting pituitary adenoma. J Neurosurg 2001, 95:285–291.

    PubMed  CAS  Google Scholar 

  45. Hoybye C, Grenback E, Rahn T, et al.: Adrenocorticotropic hormone-producing pituitary tumors: 12 to 22-year followup after treatment with stereotactic radiosurgery. Neurosurgery 2001, 49:284–291.

    Article  PubMed  CAS  Google Scholar 

  46. Zhang N, Pan L, Wang EM, et al.: Radiosurgery for growthhormone-producing pituitary adenomas. J Neurosurg 2000, 93(suppl 3):6–9.

    PubMed  Google Scholar 

  47. Shin M, Kurita H, Sasaki T, et al.: Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus. J Neurosurg 2000, 93(suppl 3):2–5.

    PubMed  Google Scholar 

  48. Pan L, Zhang N, Wang EM, et al.: Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 2000, 93(suppl 3):10–13.

    PubMed  Google Scholar 

  49. Lin CL, Wu TJ, Machacek DA, Jiang NS, Kao PC: Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 1997, 82:151–155.

    Article  PubMed  CAS  Google Scholar 

  50. Cizza G, Nieman LK, Doppman JL, et al.: Factitious Cushing’s syndrome. J Clin Endocrinol Metab 1996, 81:3573–3577.

    Article  PubMed  CAS  Google Scholar 

  51. Findling JW, Raff H: Diagnosis and differential diagnosis of Cushing’s syndrome. Endocrinol Metab Clin North Am 2001, 30:729–747.

    Article  PubMed  CAS  Google Scholar 

  52. Freda PU, Wardlaw SL: The differential diagnosis of Cushing’s syndrome. Ann Endocrinol 2001, 62:173–179.

    Google Scholar 

  53. Newell-Price J, Trainer P, Perry L, et al.: A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol 1995, 43:545–550.

    CAS  Google Scholar 

  54. Newell-Price J, Perry L, Medbak S, et al.: A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 1997, 82:176–181.

    Article  PubMed  CAS  Google Scholar 

  55. Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC: Out-patient screening for Cushing’s syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999, 84:878–882.

    Article  PubMed  CAS  Google Scholar 

  56. Newell-Price J, Trainer P, Besser M, Grossman A: The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998, 19:647–672.

    Article  PubMed  CAS  Google Scholar 

  57. Kaltsas GA, Giannulis MG, Newell-Price JD, et al.: A Critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing’s disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999, 84:487–492.

    Article  PubMed  CAS  Google Scholar 

  58. Aron DC, Raff H, Findling JW: Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1997, 82:780–1785.

    Article  Google Scholar 

  59. Freda PU, Wardlaw SL: Clinical review 110: Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999, 84:3859–3866.

    Article  PubMed  CAS  Google Scholar 

  60. Shimon I, Melmed S: Management of pituitary tumors. Ann Intern Med 1998, 129:472–483.

    PubMed  CAS  Google Scholar 

  61. Daneshdoost L, Gennarelli TA, Bashey HM, et al.: Recognition of gonadotroph adenomas in women. N Engl J Med 1991, 324:589–594.

    Article  PubMed  CAS  Google Scholar 

  62. Feldkamp J: Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas-results of a prospective study. Clin Endocrinol 1999, 51:109–113.

    Article  CAS  Google Scholar 

  63. Chanson P, Daujat F, Young J, et al.: Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: a followup study. J Clin Endocrinol Metab 2001, 86:3009–3015.

    Article  PubMed  CAS  Google Scholar 

  64. Howlett TA, Como J, Aron D: Management of pituitary incidentalomas. A survey of British and American endocrinologists. Endocrinol Metab Clin North Am 2000, 29:223–230.

    Article  PubMed  CAS  Google Scholar 

  65. Tabarin A, Navarranne A, Guerin J, et al.: Use of ketoconazole in the treatment of Cushing’s disease and ectopic ACTH syndrome. Clin Endocrinol 1991, 34:63–69.

    CAS  Google Scholar 

  66. Orrego JJ, Barkan AL: Pituitary disorders. Drug treatment options. Drugs 2000, 59:93–106. These authors review treatment strategies for the five major types of pituitary adenomas, emphasizing the use of medical therapy for control of hormonal hypersecretion or for the replacement of hormones in those patients with pituitary insufficiency.

    Article  PubMed  CAS  Google Scholar 

  67. Schteingart DE, Tsao HS, Taylor CI, et al.: Sustained remission of Cushing’s disease with mitotane and pituitary irradiation. Ann Intern Med 1980, 92:613–619.

    PubMed  CAS  Google Scholar 

  68. Cannavo S, Squadrito S, Curto L, et al.: Results of a two year treatment with slow release Lanreotide in acromegaly. Hormone Metab Res 2000, 32:224–229.

    CAS  Google Scholar 

  69. Lamberts SW, Zweens M, Verschoor L, del Pozo E: A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine and the combination of both drugs. J Clin Endocrinol Metab 1986, 63:16–20.

    PubMed  CAS  Google Scholar 

  70. Jaffe CA, Barkan AL: Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992, 21:713–735.

    PubMed  CAS  Google Scholar 

  71. Trainer PJ, Drake WM, Katznelson L, et al.: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342:1171–1177.

    Article  PubMed  CAS  Google Scholar 

  72. Jaffe CA, Friberg RD, Barkan AL: Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest 1993, 92:695–701.

    PubMed  CAS  Google Scholar 

  73. Jaffe CA, DeMott-Friberg R, Frohman LA, Barkan AL: Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. J Clin Endocrinol Metab 1997, 82:634–647.

    Article  PubMed  CAS  Google Scholar 

  74. Besser M: Criteria for medical as opposed to surgical treatment of prolactinomas. Acta Endocrinol 1993, 129(suppl 1):27–30.

    PubMed  Google Scholar 

  75. Jaquet P: Medical therapy of prolactinomas. Acta Endocrinol 1993, 129(suppl 1):31–33.

    PubMed  Google Scholar 

  76. Webster J, Piscitelli G, Polli A, et al.: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994, 331:904.

    Article  PubMed  CAS  Google Scholar 

  77. Di Sarno A, Landi ML, Cappabianca P, et al.: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Meteb 2001, 86:5256–5261.

    Article  Google Scholar 

  78. Brue T, Pellegrini I, Gunz G, et al.: Effects of dopamine agonist CV205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992, 74:577–584.

    Article  PubMed  CAS  Google Scholar 

  79. Shimon I, Taylor JE, Dong JZ, et al.: Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone and prolactin regulation. J Clin Invest 1997, 99:789–798.

    Article  PubMed  CAS  Google Scholar 

  80. Kwekkeboom DJ, Hofland LJ, van KoetsveldPM, et al.: Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture. J Clin Endocrinol Metab 1990, 71:718–724.

    PubMed  CAS  Google Scholar 

  81. Vance ML, Ridgway EC, Thorner MO: Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab 1985, 61:580–584.

    Article  PubMed  CAS  Google Scholar 

  82. Lamberts SW, Verleun T, Oosterom R, et al.: The effects of bromocriptine, thyrotropin-releasing hormone and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro. J Clin Endocrinol Metab 1987, 64:524–530.

    PubMed  CAS  Google Scholar 

  83. Klibanski A, Shupnik MA, Bikkal HA, et al.: Dopaminergic regulation of alpha subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors. J Clin Endocrinol Metab 1988, 66:96–102.

    PubMed  CAS  Google Scholar 

  84. Greenman Y, Melmed S: Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 1994, 79:724–749.

    Article  PubMed  CAS  Google Scholar 

  85. Warnet A, Harris AG, Renard E, et al.: A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. Neurosurgery 1997, 41:786–797.

    Article  PubMed  CAS  Google Scholar 

  86. de BruinTW, Kwekkeboom DJ, Van’t VerlaatJW, et al.: Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992, 75:1310–1317.

    Article  PubMed  Google Scholar 

  87. Merola B, Colao A, Ferone D, et al.: Effects of chronic treatment with octreotide in patients with functionless pituitary adenomas. Hormone Res 1993, 40:149–155.

    PubMed  CAS  Google Scholar 

  88. Katznelson L, Oppenheim DS, Coughlin JF, et al.: Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. J Clin Endocrinol Metab 1992, 75:1318–1325.

    Article  PubMed  CAS  Google Scholar 

  89. Sassolas G, Serusclat P, Claustrat B, et al.: Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995). Hormone Res 1988, 29:124–128.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurosurgery, University of Vermont College of Medicine, Fletcher Allen Health Care-MCHV campus, 507 Fletcher House, 111 Colchester Avenue, 05401, Burlington, VT, USA

    Paul L. Penar MD, David J. Nathan MD, Muriel H. Nathan MD, PhD & Afshin Salsali MD

Authors
  1. Paul L. Penar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Nathan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Muriel H. Nathan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Afshin Salsali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Penar, P.L., Nathan, D.J., Nathan, M.H. et al. Pituitary tumor diagnosis and treatment. Curr Neurol Neurosci Rep 2, 236–245 (2002). https://doi.org/10.1007/s11910-002-0082-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-002-0082-6

Keywords

Search

Navigation